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Abstract
Photodynamic therapy (PDT) has shown to be a promising technique to treat various forms of malignant neoplasia. The
photodynamic eradication of the tumor cells is achieved by applying a photosensitizer either locally or systemically and
following local activation through irradiation of the tumor mass with light of a specific wavelength after a certain time of
incubation. Due to preferential accumulation of the photosensitizer in tumor cells, this procedure allows a selective
inactivation of the malignant tumor while sparing the surrounding tissue to the greatest extent. These features and
requirements make the PDT an attractive therapeutic option for the treatment of retinoblastoma, especially when surgical
enucleation is a curative option. This extreme solution is still in use in case of tumours that are resistant to conventional
chemotherapy or handled too late due to poor access to medical care in less advanced country. In this study we initially
conducted in-vitro investigations of the new cationic water-soluble photo sensitizer tetrahydroporphyrin-tetratosylat
(THPTS) regarding its photodynamic effect on human Rb-1 and Y79 retinoblastoma cells. We were able to show, that neither
the incubation with THPTS without following illumination, nor the sole illumination showed a considerable effect on the
proliferation of the retinoblastoma cells, whereas the incubation with THPTS combined with following illumination led to a
maximal cytotoxic effect on the tumor cells. Moreover the phototoxicity was lower in normal primary cells from retinal
pigmented epithelium demonstrating a higher phototoxic effect of THPTS in cancer cells than in this normal retinal cell
type. The results at hand form an encouraging foundation for further in-vivo studies on the therapeutic potential of this
promising photosensitizer for the eyeball and vision preserving as well as potentially curative therapy of retinoblastoma.
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Introduction
Retinoblastoma is a genetically determined tumor due to
mutations or deletions of both copies of RB1, a tumor-suppressor
gene encoding a 110 kDa nuclear protein involved in the control
of neoplastic growth [1]. The retinoblastoma protein (pRb) is
responsible for a major G1 checkpoint, blocking S-phase entry by
targeting E2F transcription factors [2]. Alterations in the pRb/
E2F pathway are commonly found in human cancers, and in the
absence of pRb multiple pathways are activated leading to
increased tumor growth [3]. Retinoblastoma arises from a mixture
of transformed retinal progenitors with Mu¨ller- and photorecep-
tor-like characteristics and bipotential differentiation status [4,5].
Retinoblastoma is the most common intraocular tumor of infancy
and early childhood affecting 1 out of 18.000 births [6]. Most cases
develop in the first or second year of life, although later
presentation can occur and very rare cases have even been
reported in adults [7]. In about 40% of patients, the disease is
bilateral denoting a hereditary form of the disease. Absence of
treatment is always fatal and patients die of intracranial extension
and disseminated disease within 2 years. While the vital prognosis
for RB is excellent in industrialized countries with cure rates
greater than 95%, in low income countries the survival ranges
between 25 to 70% [8]. Chemotherapy is adapted for early tumors
but enucleation is still a common strategy in the treatment of
retinoblastoma worldwide [9]. The use of this extreme surgical
solution is now rare in Western country but still occures due to the
development of resistance against chemotherapy agents in
advanced retinoblastoma [10]. In addition, complications may
arise from the use of radiotherapy and systemic chemotherapy,
including cataracts, radiation retinopathy and developpement of
secondary malignant neoplasms and leukemia [11–13]. In less
advanced country, however, ennucleation is still a widely used
therapy. This is due to combination of various factors including
poor network of paediatrician, limited access to medical center
with proper oncology service, cost of treatments... Resistance to
current therapeutic approaches against retinoblastoma and lack of
easily deployable strategy in less advanced countries underline the
need for the development of new and efficient therapies.
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A promising treatment for neuro-ophthalmic cancer consists in
photodynamic therapy (PDT). Discovered 100 years ago by
Hermann von Tappeiner and Oscar Raab [14], PDT requires the
simultaneous presence of a photosensitizer, light and oxygen inside
the diseased tissue. The photosensitizer accumulates in the target
cells and absorbs light at specific wavelengths. The energy is
transferred to endogenous oxygen and highly reactive oxygen
species (ROS) as well as singlet oxygen are generated. Treatment
with appropriate light doses generates ROS and directly leads to
cell death without any possible development of a resistance
mechanism [15,16]. As most of the antidrugs, photosensitizers
exhibit a higher uptake by cancer vs normal cells, thus allowing a
very selective eradication of the malignant tumor while sparing the
surrounding tissue [15,17]. Altogether PDT is rapid, it has no
long-term side effects, and most importantly stimulates the
immune system, thus maximizing the tumoricidal effect [18–20].
Here, we proposed to use as a photosensitizer the tetrahy-
droporphyrin-tetratosylat (THPTS), a pure, positively charged,
water soluble and chemically stable synthetic substance [17].
THPTS accumulates very strongly in the cancer cells compared to
healthy cells, with a tumor vs normal tissue ratio (TNTR) ranging
from 8 to 50. THPTS possesses no toxic effect in pre-incubated
cells without irradiation. Consistent with the fact that positively
charged photosensitizers specifically induce the death of tumor
cells by apoptosis [21], it has been shown that THPTS-PDT
followed by light irradiation induced an efficient apoptosis in the
target cells [22]. In addition, skin photosensitivity, a typical side
effect of PDT can be neglected as the turn over of the product is
high in healthy cells [17]. Also, heat damage to the surrounding
tissue is absent as the amount of energy needed for THPTS
activation is reduced. THPTS-PDT, in combination with an
appropriate laser light at 760 nm, penetrates up to 25 mm of
tissue, much deeper than commonly used photosensitizers [22].
The higher penetration depth of THPTS-PDT enables the
treatment of tumors with a size of ca. 15 mm which are not
within the scope of actual photosensitizers [17]. Altogether
THPTS exhibits several advantages compared to the photosensi-
tizers actually used in clinic and may consist in a new anticancer
drug to target retinoblastoma cells while sparing the vision.
Materials and Methods
Human retinoblastoma cultures
Prior to survival assay and RT-PCR, human retinoblastoma cell
lines Y79 (#HTB-18, ATCC, Manassas, VA) and WERI Rb-1 (#
HTB-169, ATCC) were maintained in flasks with DMEM
Glutamax medium (#21885, Invitrogen) containing 1000 U/ml
penicilin and streptavidin (#15140-122, Invitrogen) and 10% fetal
calf serum (#16000-044, Invitrogen) at 37uC, 85% humidity and
5% CO2. For immunocytochemistry, Y79 and WERI-Rb-1 cells
were cultured on BD Falcon 8 wells glass chambers slides
(#354108, Becton-Dickinson, Franklin Lakes, NJ) previously
coated with 25 mg/ml of laminin-1 (L2020, Sigma, St. Louis,
MO). Cells were seeded at 60.000 cells/cm2 and cultured for a
week in DMEM Glutamax medium (#21885, Invitrogen)
supplemented with 250 mM dibutyryl cyclic AMP (Sigma)
1000 U/ml penicilin and streptavidin (#15140-122, Invitrogen)
and 10% Lipumin (#F11-014, PAA Laboratories, Pasching). As
described previously [23,24], those conditions allowed the
adherence of the retinoblastoma cell lines on the glass surface,
therefore easing the immunocytochemistry staining process and
analysis.
Primary human retinal pigmented epithelium cell
cultures
The use of human material was approved by the Ethics
Committee of the University of Leipzig, and all procedures were
performed in accordance with the Declaration of Helsinki. All
tissues were obtained after receiving written informed consent
from the patients or their legal representatives. Copies of the
consents were sent to the Ethics Commitee of the University for
archiving. Eyes were obtained from adult post-mortem donors
without reported eye diseases within 48 h of death. Primary
human RPE cells were isolated from the eyes as described
previously [25]. The obtained RPE cells were cultured in flasks
(Greiner) in Ham F-10 medium containing 10% fetal calf serum,
Glutamax II, and penicillin/streptomycin at 37uC in a 5% CO2
atmosphere.
Photodynamic therapy on retinoblastoma and retinal
pigmented epithelium cells
For each sample, 500 ml of stock solution of the different cell
suspensions (Y79; WERI Rb-1 cell lines and RPE cells) at 106
cells/ml were cultured on 12 well plates (Greiner Bio-One,
Flickenhausen Germany). The samples were treated with the
respective amount (0, 25 mg/ml; 50 mg/ml; 100 mg/ml; 200 mg/
ml) of THPTS made from a stock solution at 10 mg THPTS/ml
in water, prepared extemporaneously. All samples were then
placed in the incubator for different incubation periodes (0.5 h, 1.5
h, 3 h, 6 h, 12 h, and 24 h). After the administration of THPTS, all
samples were handled under a halogen desk lamp equipped with a
monochrome filter at 325 nm in order to prevent unintended
activation of the photosensitizer. To avoid THPTS to interfere
with the proliferation assay we performed three washing steps with
PBS. Retinoblastoma and RPE cells (with prior trypinisation) were
collected into 1.5 ml tubes and centrifuged at 1000 rpm for 5 min.
the supernatant was discarded and the remaining pellet re-
dissolved in 500 ml PBS. After the third centrifugation the pellet
was re-dissolved in 500 ml fresh THPTS-free culture medium. To
ensure an equal distribution of the laser light, 100 ml of cell
suspension was then distributed in 96 well plates prior to
irradiation.
Except for the dark toxicity assay, all samples were then
irradiated with 60 J/cm2 at 760 nm using a diode laser (Ceralas
D, Ceramoptec GmbH, Bonn, Germany). After incubation for
24 hours, a survival assay using tetrazolium salt wst-1
(#05015944001, Roche, Mannheim Germany) was performed
by adding 10 ml of wst-1 reagent to each well. After 2 hours the
resulting colorimetric reaction of the formazan dye generation was
measured at 450 nm and 650 nm on a microplate reader
(Spectramax 250, Molecular Devices, Sunnyvale, CA). The
amount of formazan dye formed reflected the number of
metabolically active cells in the culture and therefore, the
measured absorbance directly correlated to the number of viable
cells. Background value obtained for the medium alone was
withdrawn from the resulting data.
Clearance of THPTS
To investigate the dynamic of the compound clearance, 100 ml
from the 500 ml of the different cell samples (prepared as described
above) were distributed in 96-well plates, irradiated and analyzed
after 24 hours of incubation. The remaining 400 ml of each cell
samples were transferred into a new 12-wells plate and maintained
in the incubator for 30 hours. After this additional incubation, the
samples were washed as described above and 100 ml of the
different cell suspensions were then transferred onto a 96-well
THPTS and Retinoblastoma
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plate, irradiated and analyzed 24 hours later, now leaving 300 ml
for another 30 hours to repeat the procedure once again. This
allowed us to analyze the changes in THPTS-PDT efficiency after
long incubation periods reflecting THPTS clearance from the
cells.
Total RNA extraction and cDNA synthesis
For real-time-PCR analysis, each 500 ml sample of the stock
solution of both retinoblastoma cell lines was prepared on 12-well
plates as described above. All samples except control were supplied
with THPTS at a concentration of 200 mg/ml and incubated for
three hours (37u, 5% CO2). After incubation the samples were
washed three times and 100 ml were then transferred onto a 96-
well plate and irradiated with the laser. All samples were then
again returned to the incubator for various periods of time (0.5 h;
1.5 h; 3 h; 4.5 h; 6 h; 12 h; 24 h). After the respective incubation
time, 350 ml of RLT-Buffer (Qiagen, Hilden, Germany) were
added to each sample to disrupt the cells and total RNA was
extracted from Rb-cells by using the RNeasy Mini Kit (Qiagen).
The quality of the RNA was analyzed by agarose gel electropho-
resis. The A260/A280 ratio of optical density was measured using
the GeneQuantpro device (Pharmacia, Uppsala, Sweden), and was
between 2.0 and 2.2 for all RNA samples, indicating sufficient
quality. After treatment with DNase I (Roche, Mannheim,
Germany), cDNA was synthesized from 1 mg total RNA using
the RevertAid H Minus First Strand cDNA Synthesis kit
(Fermentas, St. Leon-Roth, Germany).
Real-time RT-PCR
The relative mRNA levels of the different genes (hATF3; hJUN;
hHSP70B; hp27; hGADD45G; hGADD153; hHSP105) in
THPTS-PDT-treated retinoblastoma cells were determined in
comparison to the levels of the controls (no THPTS-PDT).
Quantitative real-time RT-PCR was performed with the Single-
Color Real-Time PCR Detection System (BioRad, Munich,
Germany) using the following forward/reverse primer pairs
sequences (59-39; size of the endproduct in bp): hGAPDH,
GCAGGGGGGAGCCAAAAGGGT/TGGGTGGCAGTGAT-
GGCATGG (219); hATF3, TGTCCATCACAAAAGCCGA0-
GGTAGC/CTCCTTCTTCTTGTTTCGGCACT (107); hJUN,
GCCAGAGCCCTGTTGC/GAAGGTCGTTTCCATCTTTG-
C (102); hHSP70B, GTGGGGGCACCTTCGATGTGT/TG-
GTTCACGAGCCGGTTGT (118); p27/KIP1, AAGCGAC-
CTGCAACCGACGATTCTT/GCTCCACAGAACCGGCAT-
TT (100); hGADD45G, CGAGTCAGCCAAAGTCTTGAA-
CGTG/GAAAGCCTGGATCAGCGTAAA (121); hGADD153,
TGTCTTCAGATGAAAATGGGGGTAC/CAGAGAAGCAG-
GGTCAAGAGT (95); hHSP105, CCCCGTCAGTCATAT-
CATTTGG/TGTTTGCATGAGTGATTTGCTG (81).
The PCR solution contained 1 ml cDNA, specific primer set at
0.2 mM each and 10 ml of a 26 mastermix (QuantiTect SYBR
Green PCR Kit; Qiagen) in a final volume of 20 ml. The following
conditions were used: initial denaturation and enzyme activation
(one cycle at 95uC for 15 min); denaturation, amplification and
quantification, 45 cycles at 95uC for 30 s, 58uC for 30 s, and 72uC
for 1 min; melting curve, 55uC with the temperature gradually
increased (0.5uC) up to 95uC. All PCR data were checked for
homogeneity by dissociation curve analysis. Fluorescence changes
were monitored after each cycle, Ct (threshold cycle) values for
amplification of the respective mRNA and GAPDH mRNA were
defined, and the levels of the different mRNA in each sample were
standardized to the endogenous hGAPDH level. Comparable
efficiencies for targeted gene and hGAPDH mRNA amplification
were determined by analyzing serial cDNA dilutions. The changes
in mRNA expression for the respective genes were calculated
according to the 22DDCT method (CT, cycle threshold), with DCT
= CTtreated2 CTcontrol and DDCT = DCTtarget gene – DCTcontrol.
The amplified bands were analyzed by standard agarose gel.
Immunocytochemistry and live recording
After laser illumination, Y79 cells were fixed for 15 minutes in a
4% formaldehyde solution in PBS before immunostaining process.
Non specific sites were blocked and cells were permeabilized using
a solution of 30% casblock (InVitrogen) and 0.2% Triton X100 in
PBS for 30 minutes at RT. Actin filaments were revealed using
phalloidin coupled to Alexa 488 (#A12379 InVitrogen) and used
at 1/50. DAPI (InVitrogen) nuclear staining was achieved in the
last washing steps. Slides were mounted with Fluoromount-G
(EMS, Hatfield, USA), observed using a Zeiss Axioplan 2
fluorescent microscope and picture taken with a Axiocam MRc5
digital camera coupled to Axiovison 4.6 software (Carl Zeiss, Jena
Germany). Time lapse imaging was achieved using 100 mg/ml
THPTS incubated with cells for 1.5 h. After compound activation,
images were taken every 30 seconds for 40 minutes using an
inverted microscope (Aviovert 25, Carl Zeiss) coupled to a digital
camera.
For subcellular localization of THPTS, Y79 cells were
incubated for 2 h at 37uC with 200 nM MitoTracker Green FM
(M7514, Invitrogen, Karlsruhe, Germany) and 200 mM THPTS.
The cells were visualized at a LSM 5 Pascal (ZEISS, Oberkochen,
Germany) laser scanning microscope using an Achroplan 6360.95
water immersion objective. M7514 was excited at 488 nm and
emission was detected at 505–530 nm; THPTS was excited at
514 nm and detected using a long pass LP 650 nm filter set. A
FRET (Fo¨rster Resonance Energy Transfer) system was developed
to visualize THPTS using excitation at 488 nm exciting the
M7514, which in turn excited nearby THPTS with fluorescent
emission at 516 nm. The detection of THPTS was performed with
the same LP 650 nm filter set. For oxidative stress visualization,
mitochondria were labeled (200 nM, 2h, 37uC) with the chemi-
cally reduced forms of the tetramethylrosamine (MitoTracker
Orange CM-H2TMRos, M7511, Invitrogen) with or without
200 mM THPTS incubation. M7511 is not fluorescent in reduced
form. M7511 has an excitation maximum at 560 nm and would
emit at 575 nm only if oxidized. To achieve fluorescence
separation at best, we excited M7511 at 488 nm (about 10%
efficiency) and detected the fluorescence with a band pass filter set
(560–615 nm). THPTS was excited at 514 nm (99% efficiency)
and detected using a long pass filter set (.650 nm). Though
M7511 shows 30% excitation efficiency at 514 nm, the emission
above 650 nm is well below 1%, ensuring appropriate separation
of the dyes in multi-track laser scanning microscopy.
Oxidation of M7511 was enhanced by irradiation of the cells
with UV-light using a DAPI filter set (,300 nm – 420 nm
transmission).
Data analysis
Each experiment was repeated at least 3 times per condition.
Bar diagrams display the means of cells survival rate (6 SEM).
Comparisons between the means across all experimental condi-
tions were made by Welch T-Test. P , 0.05 was considered
statistically significant.
Results
Effect of THPTS-PDT on retinoblastoma cell lines
We first incubated the Rb-cell-lines with THPTS for different
periods of time (0.5 h, 1.5 h, 3 h, 6 h, 12 h and 24 h) at a
THPTS and Retinoblastoma
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concentration of 200 mg/ml in order to investigate the effective-
ness of the PDT as well as the dark toxicity of the compound
depending on the application time (Figure 1). At different time
points the medium was replaced by THPTS-free medium and the
corresponding samples were then irradiated with the 760 nm laser.
After another 24 hours (at 37uC; 5% CO2; darkness) the viability
was analyzed with WST-1 assay (Roche, Mannheim Germany).
This allowed us to gain information on the dynamics of the uptake
of the compound into the cells and to determine the most effective
time of incubation with THPTS. We found that there was no
measurable dark toxicity within the tested period of time using
200 mg/ml of THPTS. In addition the sole laser irradiation of the
cells without THPTS led to no significant changes in the survival
rates compared to the controls. Using 200 mg/ml THPTS
followed by PDT, demonstrated the cytotoxic effect of the
treatment even for the shortest incubation time tested, as the
survival dropped below 35% for the two cells lines tested after 0.5
h (30.2 +/–8.0% and 34.9 +/– 4.1% for WERI Rb-1 and Y79
respectively). The samples submitted to THPTS-PDT showed a
maximal effect on the cell survival after 1.5 h (WERI Rb-1) and 3
h (Y79) of incubation with the compound, respectively. Beyond
these times points, the effectiveness of the induced photo-killing of
retinoblastoma cells reached 100% as was no detectable metab-
olism of the formazan in thoses cells compared to the control
situation (p,0.001).
Dose-dependent and incubation effects of THPTS-PDT
As a next step we compared the effect of different concentra-
tions (25 mg/ml, 50 mg/ml, 100 mg/ml, 200 mg/ml) of THPTS on
the viability of WERI Rb-1 cells (Figure 2). The samples were
again incubated with the respective amount of the compound for
1.5 h and 3 h, treated with the laser and then tested for viability
using the WST-1 assay. The results show a clear dose-dependent
effect of the THPTS-PDT with survival rates of 77.3%, 65.9%
37.7% and 0.4% respectively after 1.5h. At lower concentrations
(25, 50 and 100 mg/ml), there was also a significant dependency
on the application time (p,0.001 for all time points). When
incubated for 3 hours with 25 mg/ml, 50 mg/ml, 100 mg/ml
THPTS, the survival was decreased to 41.5%, 32.2% and
10.6% respectively, corresponding to 1.8, 2.0 and 3.5 fold
increases of the photo-killing just by doubling the incubation time
of the respective THPTS concentration.
Effect of THPTS-PDT on cell survival in non-malignant
retinal cells compared to retinoblastoma
To explore the differential cytotoxicity of THPTS-PDT on non-
degenerated retinal cell populations, we compared the phototoxic
effect in retinoblastoma (WERI Rb-1) and normal primary human
retinal pigmented epithelium cells (hRPE). We measured the
survival rate of RPE cell treated 3h with the higher dose of
THPTS (200 mg/ml) and observed that normal primary cells
survived at 32.63 +/– 1.48%, while photokilling of Rb cells with
this THPTS concentration and incubation time was maximal. In
addition, in absence of laser activation (dark toxicity), RPE
survival with those parameters was found to be at 106,99 +/–
7.76%. THPTS had therefore no cytotoxic effect per se on RPE
cells in vitro and affected RPE cells to a lower extend when
activated by laser. As seen in figures 1 and 2, cell survival can be
modulate by changing incubation time and THPTS concentra-
tion. In order to allow a high photokilling of tumor cells together
with a limited effect on normal cell, we lowered THPTS
concentration on Rb and RPE cells and modulated the lenght of
incubation with the photosensitizer. We incubated both cell
cultures with THPTS at 50 mg/ml and 100 mg/ml for 1.5 h, 3 h
and 6 h before we supplied them with fresh THPTS-free medium
and administered the laser irradiation (Figure 3). While after 1.5 h
of incubation the WERI Rb-1 cells showed survival rates of 62.9%
(50 mg/ml) and 40.3% (100 mg/ml), the hRPE still presented
88.2% and 84.5% of survival, respectively. This represents a 1.4
fold (p,0.05) survival increase for RPE vs Rb cells treated with
50 mg/ml of THPTS and 2.1 fold (p,0.01) survival increase when
treated with 100 mg/ml THPTS for 90 minutes. The relative
difference was even stronger after 3 hours of incubation, as WERI
Rb-1 survived to 29.2% and 13.5% and hRPEs to 83.7% and
42.4% when using 50 and 100 mg/ml THPTS respectively. This
correspond to a 2.9 (p,0.01) and 3.1 (p,0.001) fold increase of
survival to the treatment for hRPE vs Rb with those settings. After
6 hours of incubation the PDT treatment did not further affect the
survival, indicating that the maximal effect on these cells with
these parameters was reached.
Turnover of THPTS
We examined whether THPTS is released by the cells when not
being activated by laser light. We incubated the WERI Rb-1 cells
with THPTS (200 mg/ml) for 0.5 h, 1.5 h, 3 h and 6 h (Figure 4).
We then treated fractions of the respective samples with laser
irradiation and then measured the survival rates (time point 1).
The survival rates were found between 0% and 4% for all of the
four conditions. The remaining fractions of the cultures were
supplied with fresh THPTS-free medium. After allowing the cells
to release the compound into the medium for about 30 h (time
point 2 = time point 1 + 30h) we again irradiated a fraction of the
cell culture and obtained survival rates of 68.2% for the 0.5 h
samples and 46.6%, 49.4% and 43.4% for the 1.5, 3, and 6 hours
samples, respectively. After repeating the same procedure for
another 30 h (time point 3 = time point 1 + 60 h) we obtained
survival rates of 67.9%, 78.7%, 68.7% and 121.8%, respectively,
relative to controls. Each washing step resulted in a 500x dilution
of the active compound present in the medium. It is therefore
unlikely that the release of the compound is affected by an
accumulation in the medium and we can consider the clearance of
the compound to be unrestricted to the greatest extent. Survival
rates reflect the amount of compound still present in the cell.
Survival increases observed at time point 3 ranged from 1.8 to 1.5
fold compared to survival values at time point 2, thus reflecting a
corresponding loss of efficiency of PDT due to THPTS turnover in
Rb cells. Based on these observations and the reported properties
of the compound [17], 30 h time point was found close to the half
life of THPTS in the cells.
Gene expression
By quantitative RT-PCR (Figure5), we furthermore determined
the effect of THPTS-PDT on the mRNA-levels of genes related to
apoptosis (hATF3; hJUN; hHSP70B) or stressful growth arrest
(hp27) including DNA damage (hGADD45G; hGADD153) and
other severe stress (hHSP105) [26]. We were able to show that the
mRNA levels of several genes related to cellular damage and
apoptosis were in great parts strikingly increased. In this regard we
observed significant (p,0.05 to p,0.001) up-regulation of mRNA
levels of ATF3, JUN and HSP70B, demonstrating the activation of
apoptotic pathways. The enhancements ranged from 67-fold
increases for ATF3 and 99-fold increases for JUN to well above
900-fold increases of HSP70B transcripts which are considered to
be specific for Fas-induced apoptosis [27]. The demonstrated
increases of gene transcripts related to cellular stress (HSP105) and
severe DNA-damage in particular (GADD45G and GADD153)
give further evidence of the cellular damage induced by the
THPTS-PDT within the retinoblastoma cells. Significant 16- to 21
THPTS and Retinoblastoma
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Figure 1. THPTS-PDT on retinoblastoma cell lines. In vitro cell survival analysis of WERI Rb-1 (A) and Y79 (B) cells irradiated with laser after
incubation with THPTS (200 mg/ml) for 0.5 h, 1.5 h, 3 h, 6 h, 12 h or 24 h (red bars) showed a minimal survival rate of 0% –5% after an incubation time
of 1.5 hours (WERI Rb-1) or 3 hours (Y79). When incubated with THPTS (200mg/ml) without irradiation (dark toxicity) for 0.5 h, 1.5 h, 3 h, 6 h, 12 h or 24
h (brown bars), the survival rate relative to control varied from 85.2% (3 h) to 107.7% (24 h) in WERI Rb-1 and from 100.0% to 141.1% in Y79. Laser
irradiation alone (light orange bars) lead to no significant changes of the survival rates relative to controls.
doi:10.1371/journal.pone.0087453.g001
Figure 2. Dose and incubation time effects. The incubation of WERI Rb-1 with THPTS at concentrations of 25 mg/ml, 50 mg/ml, 100 mg/ml or
200 mg/ml for 1.5 h (red bars) lead to survival rates of 77.3%, 65.9%, 37.8% and 0.4%.respectively. An incubation time of 3 h (deep red bars) roughly
doubled the cell death rates (at the lower concentrations) with survival as low as 41.5%, 32.2% 10.6% and 0.4% respectively, (*** p,0.001 comparison
with control without THPTS; uuu p,0.001 for the comparison between 1.5h and 3h of THPTS incubation)
doi:10.1371/journal.pone.0087453.g002
THPTS and Retinoblastoma
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fold increases were recorded for the maximal relative expression of
the three gene transcripts. These findings are confirmed by up to
fourfold increases of the hp27 transcripts compared to the controls,
indicating growth arrest as a result of the subcellular damage and
ongoing apoptotic process [28].
Immunocytochemistry and live recording
Rb cells were incubated with low dose of THPTS (25 mg/ml)
for 90 min to induce a moderate oxidative stress without massive
cell death in order to visualize early events affecting the cell
morphology compared to untreated cells. Rb cells were cultured in
10% lipumin (PAA Laboratories). This allowed a good adherence
of the retinoblastoma cell lines on the glass surface, easing the
Figure 3. Rate of WERI-rb1 and primary RPE survival following THPTS treatment. As low as 50 mg/ml of THPTS induced an effect on
retinoblastoma cell line as survival dropped to 62.9% after 90 min of incubation (light blue bars). In RPE, using the same condition the survival
decreased slightly to 88.2% (light green bars). When increasing the THPTS concentration to 100 mg/ml the compound led to a reduced survival to
40.3% in retinoblastoma cell lines (deep blue bars) and only affect slightly the normal primary RPE cells over the same incubation period (84.5%, deep
green bars). Increasing the incubation to 3 hours induced a more drastic effect of THPTS even with low concentration. 50 mg/ml of THPTS induced a
survival of only 29.2% of the We-Rb1, a rate that dropped to 13.5% when using 100 mg/ml. Meanwhile the primary RPE cells survival is 83.7 and 42.4%
with the same conditions. A survival significantly higher than for Rb1. After 6h the survival is not further affected in RPE cells as it was found to be at
78.3 and 42.1 using 50 and 100 mg/ml of THPTS. In Rb cells also the survival was only slightly further affected compared to 3 h of incubation (34.3%
and 9.2% respectively). Asterisks indicate significant differences between Rb1 and RPE cells in comparable situations of concentration and incubation
length.
doi:10.1371/journal.pone.0087453.g003
Figure 4. THPTS turn over in cells. Loss of efficiency of THPTS in cells when irradiated after 30 and 60 h post incubation with 200 mg/ml THPTS for
0.5 h (lighter blue bars), 1.5 h (light blue bars), 3 h (blue bars), 6 h (deep blue bars). Survival was low as 0.1 to 4.0% when cells were irradiated right
after incubation with the compound (0.5 to 6 h). The survival rate inceased if the time before irradiation was extended to 30h, with low incubation
period of 0.5 h, the survival was already back to 68.2% and For all other incubation lengths the survival was found to be between 43.4 to 49.4% after
30 h. The loss of efficiency of THPTS was even greater after 60 h, with a survival of 121.8% for the shortest incubation with THPTS (0.5 h) and ranging
from 67.9 to 78.7% for the longer incubations. This represented a reduced efficiency for PDT of 1.79 fold for the shortest incubation and of 1.45, 1.56,
1.59 fold for the long incubation periods (1.5 to 6 h), thus approaching the half-life of the product within living cells. Dark toxicity (grey bars) after 6h
of incubation with THPTS was found to be at 100.1% without delay, 78,7% when irradiation was delayed 30h and 93.5% when delayed 60h.
doi:10.1371/journal.pone.0087453.g004
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Figure 5. Quantitative gene expression. The expression of genes related to apoptosis showed rapid and significant increases after treatment
with THPTS-PDT compared to the controls (depicted as the red line reflecting the expression baseline). Y axis corresponds to the relative expression
vs control while x axis corresponds to the different time points (0.5, 1.5, 3, 4.5, 6, 12 and 24h). The pink bars reflect the Y79 and the violet bars the
WERI Rb-1 cells. ATF3 showed a significant increase of up to 67.25 fold (p,0.01) in Y79 cells and a 19.87 fold (p,0.001) increase in WERI Rb-1 cells
within 12 hours after treatment. Maximal increase for hJUN expression was obtained with values up to 99.30 fold (p,0.001) in Y79 cells and up to
100.60 fold (p,0.05) in WERI-Rb-1, 12 and 3 hours after PDT respectively. hHSP70B was increased significantly after 1.5 and 0.5 hours for Y79(6.09
fold, p,0.01) and WERI Rb-1 (43.84 fold, p,0.001) respectively. With maximal increase values up to 584.24 fold (Y79, p,0.001) and 979.00 fold (WERI
Rb-1, p,0.001). hHSP105 levels increased significantly after 3 h and 0,5h in Y79 (1.43 fold, P,0.001) and in WERI Rb-1 cells (1.87 fold, p,0.05)
respectively; reaching a maximum of 8.55 fold (Y79, p,0.01) to 19.20 fold (WERI Rb-1, p,0.001) within 24 h. The DNA damage related mRNA levels of
hGADD45G (Y79: max. 16.81 fold increase after 12 h, p,0.001; WERI Rb-1: 6.88 fold increase after 3h, p,0.001) as well as hGADD153 (Y79: max. 21.57
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immunocytochemistry staining process and analysis [23,24]. We
used DAPI nuclear marker to identify cell nucleus damage and
phalloidin to stain the actin cytoskeleton and identify its
fragmentation. In control condition (Figure 6), Rb cells showed
a strong development of fillopodia as seen by actin cytoskeleton
staining (arrow in figure 6A and C). Nuclei were found
homogenous in diameter and exhibited similar DAPI staining
intensity (Figure 6B and C). Still, sparsely, fragmented nucleus
were identify in the culture (arrowhead in figure 6 B and C). After
THPTS-PDT treatment, actin cytoskeleton was dramatically
perturbed. Fillopodia were found mostly absent or drastically
reduced in length (Figure 6D, F) and many Rb cells detached from
the glass surface. Remaining cells exhibited a heterogeneous
nucleus aspect as seen with DAPI staining. Many fragmented
nucleus (arrowheads in Figure 6E and F) can be observed.
Condensed genomic material was detected by the increased
intensity for the DAPI signal (arrows in Figure 6E and F). Many
nuclei were found reduced in diameter compared to the control
situation. Chromatin condensations (pyknosis) preceding the
nucleus fragmentations (karyorrhexis) are considered to be typical
events in cells undergoing an apoptotic process.
Time lapse imaging was achieved on WERI-Rb1 cells treated
with 100 mg/ml THPTS by recording bright field image every 30
seconds for 45 minutes after compound activation with proper
laser illumination (Figure 7). Record started 15 minutes after laser
stimulation; however some cells presented already a massive
blebbing of their membrane (arrow in Figure 7A). After 45
minutes, those typical membrane damages can be observed in
many cells in the field (arrowhead in Figure 7B), while completely
absent of the untreated control cells culture after 45 minutes (insert
Figure 7C). Membrane blebbing has been pointed out to be a
characteristic feature of apoptosis while absent in necrotic process
[29]. The time lapse of WERI-Rb1 (Video S1) confirmed the gene
and immunocytochemistry data, demonstrating the rapid apo-
ptotic death of Rb cells following THPTS –PDT.
Subcellular distribution of THPTS
Incubation of Rb (Y79) cells with MitoTracker green (M7514)
resulted in clear staining of mitochondria (Figure 8A). Using laser
excitation at 514 nm, THPTS could be visualized with a 650 nm
long pass filter and the fluorescence distribution closely resembled
the M7514 labeling (Figure 8B), strongly accounting for a
mitochondrial localization of THPTS. No signal was detected
above 650 nm in absence of THPTS (Figure 8C). The pair of
fluorescence dyes M7514 and THPTS established a Fo¨rster
resonance energy transfer (FRET) system. Fluorescence emit by
M7514 at 516 nm can excite THPTS that would then be detected
above 650 nm (Figure 8G). Co-incubation of M7514 and THPTS
revealed this FRET mechanism as THPTS was specifically
detected in a subset of mitochondria after stimulation of
mitotracker at 488 nm only (Figure 8D-F). The red THPTS-
fluorescence not colocalized with green M7514 (arrows in Figure
8D-F) speaks in favor for a complete energy transfer from M7514
to THPTS, while remaining of M7514 fluorescence at 530–560
nm (Figure 8D,F) indicated that the donor dye was in excess.
Therefore, part of the excitation energy was still released as
photons. FRET pair indicated that THPTS was localized within a
range of less than 10 nm to M7514 demonstrating that THPTS
was indeed localized inside the Y79 mitochondria.
To further support this hypothesis we used the reduced
mitochondrial marker M7511, which only emits fluorescence in
its oxidized state. In absence of THPTS activation mitochondrial
staining was weak, indicating only few oxidized M7511 species in
the mitochondria (Figure 8H). However, the fluorescence was
markedly increased in intensity and showed wider distribution
following THPTS-PDT with UV-light using the DAPI filter set of
the microscope (Figure 8I). After 5 min of illumination, first
membrane blebbing occurred, indicating apoptosis (arrows in
Figure 8I).
Discussion
Here we identified the potential tumoricidal effect of THPTS
on two human retinoblastoma cell lines. While exhibiting no
cytotoxic effect per se, 200 mg/ml THPS was able to induce a
complete cell death once activated with a 760 nm laser beam at
60 J/cm2 and 100 mW/cm2. The maximal cytotoxic effect was
reached even with incubation time as short as 1.5 hours. In
fold increase after 12 h, p,0.01; WERI Rb-1: 11.90 fold increase after 1.5h, p,0.001) were significantly increased within the first 4.5 h after PDT for
both cell lines. The levels of hp27 were increased significantly increased in both cell lines. The maximum reached a 3.34 fold increase after 12 h (p,
0.001) for the Y79 cells and a 3.75 (p,0.05) fold increase for the WERI Rb-1 cells 4.5 h after the treatment. Note that for hHSP70B, y axis is in log scale.
doi:10.1371/journal.pone.0087453.g005
Figure 6. Immunocytochemistry. Y79 cells were cultured in 10%
lipumin and incubated with low dose of THPTS (25 mg/ml) for 90 min.
After formaldehyde fixation, cells were stained with DAPI nuclear
marker and phalloidin coupled to Alexa 488. In control without laser
illumination Rb cells showed a strong development of filopodia as seen
by actin cytoskeleton staining (arrow in A and C). Nuclei were found
homogenous in diameter and for DAPI staining intensity (B and C).
Rarely, fragmented nucleus can be identified (arrowhead in B and C).
THPTS-PDT treatment induced a reduction of filopodia (D, F) and many
Rb cells exhibited heterogeneous nucleus aspect as seen with DAPI
staining (E, F). Many fragmented nucleus (arrowheads in E and F) can be
observed. Condensed genomic material was detected by the increased
intensity for the DAPI signal (arrows in E and F). Many nuclei were found
reduced in diameter compared to the control situation. Scale bar
30 mm.
doi:10.1371/journal.pone.0087453.g006
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addition there are clear dose-dependent and an incubation length–
dependent effects, meaning that the same cytotoxic effects can be
reached with lower THPTS concentrations by increasing the
incubation time. This is of major interest to obtain the best ratio
for cancer cell death vs preservation of the surrounding normal
cells. We were indeed able to demonstrate the high specificity of
the compound for cancer cells as normal RPE cells were
significantly (50 mg/ml: p,0.05; 100 mg/ml: p,0.01; 200 mg/
ml: p,0.001) less affected by THPTS-PDT treatment. For
instance their survival after 3 h is 3 fold higher as for
retinoblastoma using 100 mg/ml of THPTS (Figure 3). These
results were in accordance with previous publication that reported
a high specificity of the compound for various tumor cell types
with a high TNTR ranging from 8 to 50 [17]. It has to be noted
that primary RPE cells in vitro do proliferate while this does not
occurs normally in vivo. Proliferating RPE cell in vitro might be
more sensitive to THPTS than RPE cell in situ due to an increased
metabolism that may facilitate the entry of THPTS in the cell. The
molecular mechanism underlying the target effect of THPTS-PDT
is still largely unknown but might be due to the well documented
increase in metabolic uptake occurring in tumor cells [30].
THPTS would then accumulate faster in cancer cells. Also, the
resting membrane potential of many cancer cells is hyperpolarized
compared to normal cells [31] and may therefore facilitate the
uptake of the positively charged THPTS present in the medium as
well as its retention in the cancer cell. Last but not least, the
mitochondrial hyperpolarization occurring in tumor cells [32] may
allow THPTS to target more specifically this subcellular
compartment leading to the high efficiency of treatment.
Functional mitochondria indeed are essential to cancer cell
development and highly sensitive to oxidative stress [33]. They
are actually considered as the Achilles heel of cancer cells and
target for tumor elimination using mitochondriotoxic compounds
[34,35]. To further analyse the mechanism of cell death induced
by THPTS-PDT in retinoblastoma we studied the quantitative
expression for mRNA of genes related to apoptosis (hATF3;
hJUN; hHSP70B) or stressful growth arrest (hp27) including DNA
damage (hGADD45G; hGADD153) and other severe stress
(hHSP105) [26]. Both retinoblastoma cell lines tested, exhibited
a massive upregulation of these genes. ATF3 encodes a pro-
apoptotic protein that mediates cytotoxic agents (i.e. ROS)
induced apoptosis in various systems [36]. hJUN in combination
with c-Fos, forms the AP-1 early response transcription factor
highly sensitive to ROS. Rapid and strong upregulation of ATF3
and hJUN mRNAs suggest an apoptotic cell death mechanism
induced by THPTS-PDT. Moreover, overexpression of hHSP70B
indicates more precisely a Fas-dependent apoptotic mechanism
[27]. Also, increased levels of the mRNA for p27Kip1 protein
typically cause cells to arrest in the G1 phase of the cell cycle
further driving apoptotic cell death [37]. GADD45G increase
reflects the stressful growth arrest conditions via treatment with
DNA-damaging agents [38]. Increased GADD153 also participate
to the arrested cell growth and promote programmed cell death, in
part via activation of AP1 target gene [39]. Last but not least, it
has been shown that cytosolic heat shock proteins such as HSP105
are preferentially induced in response to specific and localized
intramitochondrial damage [40]. The induction of apoptosis was
also suggested by the chromatin condensation (pyknotic nucleus)
and the karyorrhexis (nucleus fragmentation) seen in Rb cells
treated with mild THPTS-PDT (25 mg/ml, 90 min). Together
with cytoskeletal restructuration and membrane blebbing, those
damaged nuclei are hallmarks of the undergoing apoptotic
process. Altogether, our results demonstrate that THPTS-PDT
leads to a massive cell death via apoptotic pathway induction in
response to oxidative stress targeting the mitochondrial compart-
ment. This cytotoxic effect seems to be specific for cancer cells
while sparing the normal RPE cells to a great extend.
Advantage of PDT over other cancer therapies
Most of the commonly used cancer therapies are highly
immunosuppressive while PDT produces an acute activation of
the immune system that attracts leukocytes to treated tumors [18].
PDT might therefore increase the immunogenicity of dead tumor
cells by exposing or creating new antigens [41] and by inducing
heat-shock proteins that increase the efficiency of antigen cross-
presentation to form more effective tumor-specific cytotoxic T cells
[42]. In addition, the pro-inflammatory effects of PDT might
increase dendritic-cell migration, antigen uptake and maturation
leading to adaptive immunity [43]. PDT can promote tumor cures
and long-lasting tumor-specific memory [44], as has been shown
by the rejection of tumors on rechallenged rodent models [45–48].
Mechanism of action involves neutrophil cells infiltration and
activation of natural killer cells that are both essential for the
generation of tumor-specific primary and memory CD8 (+) T-cell
responses [43,49].
Like PDT, chemotherapy is based on the preferential uptake of
the compound by cancer cells thus leading to increased cytotoxity
in tumoral vs. healthy cells. However, contrary to photosensitizers,
chemotherapy involves compounds that are cytotoxic per se. The
tumor cell can develop an acquired resistance mechanism that will
reduce the efficiency of the treatment and leave the organism
vulnerable to relapse [50]. This is very unlikely to happen in PDT
as photosensitizers are not cytotoxic per se but rather induce
oxidative stress in the target cell via ROS. The activation of the
immune system combined with the low resistance mechanism
make PDT an ideal cancer curative treatment. However, many
technical limitations are linked to the dozen of clinically approved
photosensitizers and limit their use to few applications, mainly in
dermatology, urology and gastroenterology [51,52]. In neuro-
ophthalmology, the only clinical application for PDT is the
neovascularization associated with macular degeneration [53].
However the actual development of a new generation of
photosensitizers should definitely lead to preclinical evaluation of
Figure 7. Membrane blebbing in treated cells. WERI-RB1 cells
were incubated for 3 h with 100 mg/ml THPTS and bright field image
were recorded every 30 s for 45 min. Start (A) and endpoints (B) are
depicted, while endpoint of control culture without treatment is
represented in insert (C). Few minutes after laser illumination, some
cells already showed blebbing of the membrane (arrow in A). After 45
minutes (B) this feature was observed in many cells in culture
(arrowheads) while absent of the control culture (C). THPTS-PDT treated
cells showed therefore massive death by apoptosis. Scale bar in A,
15 mm.
doi:10.1371/journal.pone.0087453.g007
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PDT as a therapeutic option for the treatment of retinoblastoma
[54]. Its use in the handling of retinoblastoma may consist in an
promissing therapeutic alternative not only in Western countries in
case of resistant tumor forms but also in less advanced countries
due to the reduced logistic and associated costs of the PDT
treatment.
Advantage of THPTS compared to other photosensitizers
A main actual limitation of PDT is that visible light is needed to
activate most of the clinically approved photosensitizers. Visible
light cannot pass through more than 10 mm of tissue. For this
reason, PDT is usually used to treat tumors on or just under the
skin or on the lining of internal organs or cavities [55]. Therefore,
actual PDT is inefficient for treating large, pigmented or deep
tumors. In addition, high amounts of energy needed to activate
actual compounds lead to skin lesions and burns [51]. THPTS is
activated by infrared wavelength, thus limiting damages to normal
tissue while it increases the therapy depth up to 25 mm. Another
limitation is the rapid turnover (within minutes) of some
compounds that requires performing PDT immediately after
incubation with the photosensitizer [56]. Here we demonstrate
that THPTS rapidly entered the cells, as the maximal effect is
reach after 1 to 3 hours for all tested concentrations and remained
active over a long period with a half life in the range of a day,
while skin photosensibility can last for months with approved
photosensitizers (European Medicine Agency requirement
WC500024398). THPTS compound is positively charged and
therefore may target more specifically the mitochondrial com-
partment leading to faster and targeted oxydative damage [22,57].
Last but not least, TNTR of THPTS is higher than many other
commercially available photosensitizers [22].
Figure 8. THPTS subcellular localization. MitoTracker green (M7514) original scan identifying mitochondria in Y79 cells (A) and resembling to
subcellular THPTS distribution (B). (C) Control scan reveals no staining of THPTS at 488 nm excitation and detection with 650 nm long pass filter. (D-G)
FRET pair identification in Y79 mitochondria as excited at 488 nm and observed at 505–530 nm (D) and above 650 nm (E). (F) Merged images revealed
colocalization of M7514 and THPTS by double staining in numerous, though not all, mitochondria. Exclusive THPTS fluorescence distribution (arrows)
account for a complete energy transfer from M7514 at those localizations while signal seen at 505–530 nm account for an excess of donor (D, F).
M7514 and THPTS establish a FRET pair of fluorescence dyes as the emission maximum of MT7514 is 516 nm, which is the excitation maximum of
THPTS; blue colored area highlights M7514 excitation curve; pale green color indicates M7514 emission spectrum and dark green area corresponds to
the overlap with THPTS excitation spectrum (G). (H-I) Evidence for mitochondrial ROS production by THPTS excitation. Basic mitotracker M7511
fluorescence (H) was clearly enhanced following THPTS excitation at 514nm (I), indicating an oxidative process specifically due to THPTS-PDT (DAPI
filter set, 5 min). Insets in indicate M7511 fluorescence intensity histogram (H-I). Scale bar in (A) applies to all images except for (B-C) where scale bar
is shown in (C).
doi:10.1371/journal.pone.0087453.g008
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Future development
Next to in vitro study, the proof of concept for the use of
THPTS in the handling of retinoblastoma requires in vivo
experiments in which a tumor would develop among normal
surrounding retinal cells. The cohabitation of normal and tumoral
retina cells is essential to demonstrate the high specificity of
THPTS for cancer cells. There are currently two types of rodent
models for proper retinoblastoma study in vivo: xenograft and
transgenic mouse [58]. Injection of human retinoblastoma in
immunocompetent newborn rats recapitulates the developmental
environment of the human retinoblastoma [59,60]; while in a LH
beta -Tag transgenic mouse, a highly expressed transgene drives
the overexpression of the SV40 large T antigen leading to bilateral
retinal tumor development that resembles human retinoblastoma,
occupying approximately a quarter of the retinal area at 10 weeks
of age [61,62]. Both models are relevant for retinoblastoma study
because the tumors are developing in situ, within the retinal tissue,
in immune competent animals. Outcomes obtained with THPTS
may not only be beneficial for retinoblastoma handling but also for
various CNS tumors in which preservation of surrounding tissue is
critical. Among those, glioblastoma are highly aggressive brain
tumors with little or no animal model available [63]. Interestingly,
some subtypes of glioblastoma share common genetic abnormal-
ities with retinoblastomas as mutations in the RB1 specific
pathway are associated with the shortest survival in patients
affected by glioblastoma [64–66]. Thanks to the accessibility of the
retinal tissue and the many non-invasive methods of analysis
available: scanning laser ophthalmoscope, optical coherence
tomography and electroretinogramm to name a few, THPTS-
PDT on retinoblastoma in-vivo may also consist in a useful model
for glioblastoma studies
Supporting Information
Video S1 Supplementary data. Time lapse movie of
membrane blebbing in WERI-RB1 cells. RB1 were incubated
for 3 h with 100 mg/ml. Recording started 15 min after the
irradiation and THPTS and bright field image were recorded
every 30 seconds. Arrowheads indicated the blebbing spots an
hour after the irradiation. The massive blebbing suggests that
THPTS-PDT treated cells were dying by apoptosis.
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